Literature DB >> 26416737

Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

E M Alexandrova, A R Yallowitz, D Li, S Xu, R Schulz, D A Proia, G Lozano, M Dobbelstein, U M Moll.   

Abstract

Entities:  

Year:  2015        PMID： 26416737     DOI： 10.1038/nature15720

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  1 in total

1.  Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

Authors:  E M Alexandrova; A R Yallowitz; D Li; S Xu; R Schulz; D A Proia; G Lozano; M Dobbelstein; U M Moll
Journal:  Nature       Date:  2015-05-25       Impact factor: 49.962
  1 in total
  2 in total

Review 1.  Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Authors:  Xuetian Yue; Yuhan Zhao; Yang Xu; Min Zheng; Zhaohui Feng; Wenwei Hu
Journal:  J Mol Biol       Date:  2017-04-06       Impact factor: 5.469

2.  ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.

Authors:  Dun Li; Natalia D Marchenko
Journal:  Oncotarget       Date:  2017-01-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.